2016 Oct 08
Alisertib may benefit certain patients with neuroendocrine prostate cancer
Alisertib monotherapy may be effective in certain patients with clinical or pathologically defined neuroendocrine prostate cancer, according to Himisha Beltran, M.D. Read more



















